Medtronic PLC Company Profile (NYSE:MDT)

About Medtronic PLC (NYSE:MDT)

Medtronic PLC logoMedtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:MDT
  • CUSIP: 58505510
  • Web:
  • Market Cap: $113.35645 billion
  • Outstanding Shares: 1,359,027,000
Average Prices:
  • 50 Day Moving Avg: $85.48
  • 200 Day Moving Avg: $83.22
  • 52 Week Range: $69.35 - $89.72
  • Trailing P/E Ratio: 28.86
  • Foreward P/E Ratio: 15.62
  • P/E Growth: 3.49
Sales & Book Value:
  • Annual Revenue: $29.71 billion
  • Price / Sales: 3.82
  • Book Value: $36.73 per share
  • Price / Book: 2.27
  • Annual Dividend: $1.84
  • Dividend Yield: 2.2%
  • EBIDTA: $9.22 billion
  • Net Margins: 13.56%
  • Return on Equity: 12.72%
  • Return on Assets: 6.48%
  • Debt-to-Equity Ratio: 0.51%
  • Current Ratio: 1.75%
  • Quick Ratio: 1.51%
  • Average Volume: 4.31 million shs.
  • Beta: 1.02
  • Short Ratio: 1.72

Frequently Asked Questions for Medtronic PLC (NYSE:MDT)

What is Medtronic PLC's stock symbol?

Medtronic PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic PLC pay dividends? What is the dividend yield for Medtronic PLC?

Medtronic PLC declared a quarterly dividend on Friday, June 23rd. Stockholders of record on Friday, July 7th will be paid a dividend of $0.46 per share on Wednesday, July 26th. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.21%. The ex-dividend date of this dividend is Wednesday, July 5th. This is a boost from Medtronic PLC's previous quarterly dividend of $0.43. View Medtronic PLC's Dividend History.

How were Medtronic PLC's earnings last quarter?

Medtronic PLC (NYSE:MDT) posted its earnings results on Thursday, May, 25th. The company reported $1.33 EPS for the quarter, topping analysts' consensus estimates of $1.31 by $0.02. The firm had revenue of $7.92 billion for the quarter, compared to analyst estimates of $7.86 billion. Medtronic PLC had a net margin of 13.56% and a return on equity of 12.72%. Medtronic PLC's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period last year, the firm posted $1.27 EPS. View Medtronic PLC's Earnings History.

When will Medtronic PLC make its next earnings announcement?

Medtronic PLC is scheduled to release their next quarterly earnings announcement on Tuesday, August, 22nd 2017. View Earnings Estimates for Medtronic PLC.

Where is Medtronic PLC's stock going? Where will Medtronic PLC's stock price be in 2017?

23 brokerages have issued 1 year target prices for Medtronic PLC's stock. Their forecasts range from $78.00 to $103.00. On average, they anticipate Medtronic PLC's stock price to reach $90.32 in the next twelve months. View Analyst Ratings for Medtronic PLC.

What are analysts saying about Medtronic PLC stock?

Here are some recent quotes from research analysts about Medtronic PLC stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Medtronic has been observed to outperform the broader industry. All of its major business groups continue to contribute to solid top-line growth which highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. We are also encouraged by the solid growth trend, continuing in the U.S. as well as the healthy global acceptance of its advanced therapies. Apart from product innovation, Medtronic is focusing on geographical diversification of business. An impressive fiscal 2018 guidance also indicates continuance of this strong run going ahead. The company's last reported fourth quarter fiscal 2017 earnings were also impressive. Yet, escalating costs and expenses are weighing on margins. Also, unfavorable foreign exchange continues to remain a drag." (7/31/2017)
  • 2. Needham & Company LLC analysts commented, "F4Q17 revenue and EPS beat consensus and initial FY18 guidance was in line with consensus. Organic revenue growth was steady at 4.0% vs. 4.1% in F3Q17 with new products adding ~370 bps, emerging markets adding ~125 bps and services & solutions adding ~15 bps. Operating margin was above consensus and up 10 bps Y/Y (or 40 bps Y/Y CC). MDT’s product cycle remains strong with significant FY18 launches including: the Resolute Onyx DES, MiniMed 670G insulin pump, Signia powered stapler, new LigaSure instruments, Intellis spinal cord stimulator, Evolut PRO TAVR, and MRI CRT-P quadripolar system." (5/25/2017)
  • 3. BTIG Research analysts commented, "At last Friday's American College of Cardiology (ACC) meeting, two-year data on MDT's SURTAVI trial for intermediate-risk was presented. At the two-year mark, all cause death/stroke were similar for TAVR using MDT's valves (12.6%) vs. surgery (14%) though use of TAVR reduced 30-day strokes, kidney injury, afib, and hospital stay. While we were surprised TAVR was not superior to surgery as in other trials, it seems surgical results improved. Still, TAVR is at least as good with less invasiveness. While not the same trials, investors have tried to compare MDT's CoreValve to Edwards' (EW, Neutral) SAPIEN 3 based on available data. At 1 year, all-cause death and stroke were equivalent at 8.1% for CoreValve and 8.4% for SAPIEN 3. Overall, patient selection (EW's intermediate risk pool may have had more comorbidities) and device design (MDT mainly used its older valve) make it tough to directly compare both trials; but we believe the valves are essentially equivalent and either one should be chosen over surgery." (3/20/2017)
  • 4. Wedbush analysts commented, "Medtronic's broad product portfolio allows the company to navigate through temporary disruptions it might encounter in any given business unit, and today's FY3Q17 earnings results showcased management's ability to leverage its size and recover more quickly than we had expected from its disappointing FY2Q17 performance reported in November. With MDT's share price having mostly recovered from the post FY2Q17 selloff, we believe current valuation levels adequately reflect MDT's risk/reward profile and prefer to wait on the sidelines for a better entry point. ' FY3Q17 revenue of $7,283 million (+6% yr/yr, ex-FX) beat consensus revenue estimate of $7,220 million. Revenue from all four segments exceeded consensus, with the biggest contribution from Minimally Invasive Therapies Group (MTIG) and Diabetes' Our $85 PT is based on applying a 16x P/E multiple on our MDT forward EPS estimate, 12 months hence." (2/22/2017)
  • 5. Evercore ISI analysts commented, "MDT started 2017 with a solid execution, highlighted by all around revenue beat and operating margins that were generally in line with ST (came in above us). The importance of this Q cannot be underestimated in our mind, as sentiment had turned negative (post a disappointing 1H) and the stock multiple (3-6x discount to peer group) was see-sawing precariously at ~15-16x P/E. While the bar had been lowered, MDT needed to deliver to flawless Q to instill investor confidence and start the path towards multiple correction (vs. group). The company began its first step, highlighted by a solid revenue beat, driven by high single digit growth in CR&HF. This is a key segment, and the ~8% growth should provide comfort against the bear thesis of competitive share losses / replacement cycle headwinds. We were also encouraged to see ~30% growth in TAVR, and a full rollout of the 34mm valve (launched only in 50% of centers) plus Intermediate Risk approval in early 2018 bodes well. Other key drivers in 2018 include the full commercial launch of 670G in Diabetes, Resolute Onyx launch, continued growth in AF, Link, DCBs, and the continued turnaround in Spine provides incremental confidence in MDT being able to sustain ~4% organic topline in the medium term. The second leg of value creation will rest on margin expansion, with the ST still skeptical of the company's ability to show margin expansion on a reported basis (including the impact of Fx hedges). We believe that the margin expansion thesis will play out in 2018, and will play a huge role in MDT's ability to close its P/E gap vs. peer group average. We expect this combination of a potential multiple reflation trade along with upside from capital deployment (incremental ~$3 Bn could potentially be accessible in near term post IRS settlement) to drive value for investors over the next 12 months." (2/21/2017)

Who are some of Medtronic PLC's key competitors?

Who owns Medtronic PLC stock?

Medtronic PLC's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.71%), BlackRock Inc. (6.59%), State Street Corp (4.53%), FMR LLC (3.80%), Franklin Resources Inc. (2.81%) and Capital Research Global Investors (2.31%). Company insiders that own Medtronic PLC stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic PLC.

Who sold Medtronic PLC stock? Who is selling Medtronic PLC stock?

Medtronic PLC's stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, FMR LLC, Capital Research Global Investors, State Street Corp, Capital Guardian Trust Co., Dodge & Cox, Standard Life Investments LTD and Bank of New York Mellon Corp. Company insiders that have sold Medtronic PLC stock in the last year include Bryan C Hanson, Hoedt Rob Ten, Hooman Hakami, Kendall J Powell, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic PLC.

Who bought Medtronic PLC stock? Who is buying Medtronic PLC stock?

Medtronic PLC's stock was acquired by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, Alliancebernstein L.P., BlackRock Inc., Vanguard Group Inc., Sanders Capital LLC, Principal Financial Group Inc., Koch Industries Inc. and American Century Companies Inc.. Company insiders that have bought Medtronic PLC stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic PLC.

How do I buy Medtronic PLC stock?

Shares of Medtronic PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medtronic PLC's stock price today?

One share of Medtronic PLC stock can currently be purchased for approximately $83.41.

MarketBeat Community Rating for Medtronic PLC (NYSE MDT)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  791 (Vote Outperform)
Underperform Votes:  495 (Vote Underperform)
Total Votes:  1,286
MarketBeat's community ratings are surveys of what our community members think about Medtronic PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Medtronic PLC (NYSE:MDT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.61)
Consensus Price Target: $90.32 (8.28% upside)

Analysts' Ratings History for Medtronic PLC (NYSE:MDT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/21/2017Royal Bank Of CanadaReiterated RatingBuy$90.00LowView Rating Details
8/3/2017Jefferies Group LLCReiterated RatingBuy$103.00LowView Rating Details
7/31/2017Deutsche Bank AGSet Price TargetBuy$96.00LowView Rating Details
7/18/2017Oppenheimer Holdings, Inc.Reiterated RatingBuyLowView Rating Details
7/12/2017Wells Fargo & CompanyReiterated RatingOutperformLowView Rating Details
7/6/2017William BlairReiterated RatingOutperformMediumView Rating Details
5/30/2017BMO Capital MarketsBoost Price TargetOutperform$87.00 -> $94.00LowView Rating Details
5/30/2017Morgan StanleyBoost Price TargetEqual Weight$84.00 -> $86.00LowView Rating Details
5/28/2017Barclays PLCReiterated RatingOverweight$92.00 -> $94.00LowView Rating Details
5/28/2017Cowen and CompanyReiterated RatingOutperform$86.00 -> $95.00LowView Rating Details
5/28/2017Stifel NicolausReiterated RatingHold$84.00 -> $91.00LowView Rating Details
5/28/2017Evercore ISIReiterated RatingOutperform$88.50 -> $91.00LowView Rating Details
5/26/2017CIBCReiterated RatingBuyLowView Rating Details
5/25/2017Needham & Company LLCReiterated RatingBuy -> Buy$91.00 -> $95.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$87.00LowView Rating Details
4/20/2017Northland SecuritiesReiterated RatingHold$80.00MediumView Rating Details
3/20/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
2/23/2017Leerink SwannBoost Price TargetMarket Perform$80.00 -> $85.00N/AView Rating Details
2/22/2017WedbushReiterated RatingNeutral$85.00N/AView Rating Details
1/3/2017Bank of America CorporationDowngradeBuy -> Neutral$78.00N/AView Rating Details
1/3/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$84.00 -> $79.00N/AView Rating Details
8/25/2016Credit Suisse GroupReiterated RatingOutperform$92.00N/AView Rating Details
8/23/2016Citigroup Inc.Initiated CoverageBuy$63.98 -> $102.00N/AView Rating Details
6/20/2016ArgusReiterated RatingHold -> HoldN/AView Rating Details
6/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$93.00 -> $94.00N/AView Rating Details
6/13/2016SunTrust Banks, Inc.Boost Price TargetBuy$93.00 -> $98.00N/AView Rating Details
6/8/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$86.00N/AView Rating Details
(Data available from 8/21/2015 forward)


Earnings History for Medtronic PLC (NYSE:MDT)
Earnings by Quarter for Medtronic PLC (NYSE:MDT)
Earnings History by Quarter for Medtronic PLC (NYSE MDT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/22/2017$1.08N/AView Earnings Details
5/25/2017Q4 17$1.31$1.33$7.86 billion$7.92 billionViewN/AView Earnings Details
2/21/20171/31/2017$1.11$1.12$7.22 billion$7.28 billionViewListenView Earnings Details
11/22/2016Q217$1.11$1.12$7.46 billion$7.35 billionViewListenView Earnings Details
8/25/2016Q117$1.01$1.03$7.17 billion$7.20 billionViewListenView Earnings Details
5/31/2016Q416$1.26$1.27$7.49 billion$7.57 billionViewListenView Earnings Details
3/1/2016Q316$1.06$1.06$6.99 billion$6.93 billionViewListenView Earnings Details
12/3/2015Q216$1.00$1.03$7.08 billion$7.06 billionViewListenView Earnings Details
9/3/2015Q116$1.01$1.02$7.03 billion$7.27 billionViewListenView Earnings Details
6/2/2015Q415$1.11$1.16$7.18 billion$7.30 billionViewListenView Earnings Details
2/17/2015Q3$0.97$1.01$4.25 million$4.32 millionViewListenView Earnings Details
11/18/2014Q2$0.96$0.96$4.37 million$4.40 millionViewListenView Earnings Details
8/19/2014Q115$0.92$0.93$4.25 billion$4.27 billionViewListenView Earnings Details
5/20/2014Q414$1.12$1.12$4.58 billion$4.60 billionViewListenView Earnings Details
2/18/2014Q314$0.91$0.91$4.15 billion$4.20 billionViewListenView Earnings Details
11/19/2013Q214$0.90$0.91$4.18 billion$4.20 billionViewListenView Earnings Details
8/20/2013Q1 2014$0.88$0.88$4.11 billion$4.10 billionViewListenView Earnings Details
5/21/2013Q4 2013$1.03$1.10$4.39 billion$4.50 billionViewListenView Earnings Details
2/19/2013Q3 2013$0.91$0.93$4.03 billion$4.03 billionViewListenView Earnings Details
11/20/20120.88$0.88$4.10 billionViewN/AView Earnings Details
8/21/2012$0.85$0.85ViewN/AView Earnings Details
5/22/2012$0.98$0.99ViewN/AView Earnings Details
2/21/2012$0.84$0.88ViewN/AView Earnings Details
11/22/2011$0.82$0.84ViewN/AView Earnings Details
8/23/2011$0.79$0.79ViewN/AView Earnings Details
5/24/2011$0.93$0.90ViewN/AView Earnings Details
2/22/2011$0.84$0.86ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Medtronic PLC (NYSE:MDT)
2017 EPS Consensus Estimate: $4.62
2018 EPS Consensus Estimate: $4.93
2019 EPS Consensus Estimate: $5.39
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20177$1.00$1.15$1.03
Q2 20177$1.10$1.37$1.16
Q3 20177$1.10$1.15$1.12
Q4 20177$1.29$1.34$1.31
Q1 20186$1.07$1.15$1.10
Q2 20186$1.14$1.20$1.17
Q3 20186$1.17$1.27$1.23
Q4 20186$1.35$1.46$1.43
Q1 20192$1.20$1.21$1.21
Q2 20192$1.26$1.29$1.28
Q3 20193$1.34$1.36$1.35
Q4 20192$1.56$1.57$1.57
(Data provided by Zacks Investment Research)


Current Dividend Information for Medtronic PLC (NYSE:MDT)
Most Recent Dividend:7/26/2017
Annual Dividend:$1.84
Dividend Yield:2.21%
Dividend Growth:24.20% (3 Year Average)
Payout Ratio:63.67% (Trailing 12 Months of Earnings)
37.47% (Based on This Year's Estimates)
34.46% (Based on Next Year's Estimates)
Track Record:39 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Medtronic PLC (NYSE:MDT)

Dividend History by Quarter for Medtronic PLC (NYSE MDT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Medtronic PLC (NYSE:MDT)
Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 83.54%
Insider Trades by Quarter for Medtronic PLC (NYSE:MDT)
Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)
Insider Trades by Quarter for Medtronic PLC (NYSE:MDT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/17/2017Bryan C. HansonEVPSell12,000$88.57$1,062,840.00View SEC Filing  
6/21/2017Richard H AndersonDirectorBuy5,600$88.90$497,840.00View SEC Filing  
3/20/2017Hoedt Rob TenEVPSell50,757$81.58$4,140,756.06View SEC Filing  
3/15/2017Omar IshrakCEOSell95,000$82.82$7,867,900.00View SEC Filing  
3/2/2017Hooman HakamiEVPSell52,316$82.33$4,307,176.28View SEC Filing  
12/13/2016Robert C. PozenDirectorBuy13,660$73.21$1,000,048.60View SEC Filing  
11/23/2016James T. LenehanDirectorBuy2,000$73.27$146,540.00View SEC Filing  
9/27/2016Richard KuntzVPSell17,141$86.70$1,486,124.70View SEC Filing  
9/26/2016Richard KuntzVPSell25,199$86.67$2,183,997.33View SEC Filing  
9/15/2016Kendall J. PowellDirectorSell7,907$85.45$675,653.15View SEC Filing  
9/15/2016Omar IshrakCEOSell61,925$84.93$5,259,290.25View SEC Filing  
8/29/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00View SEC Filing  
7/26/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00View SEC Filing  
7/15/2016Geoffrey MarthaEVPSell3,766$88.26$332,387.16View SEC Filing  
7/13/2016Gary Lee EllisEVPSell35,495$88.64$3,146,276.80View SEC Filing  
7/13/2016Shirley A JacksonDirectorSell2,104$88.64$186,498.56View SEC Filing  
7/6/2016Carol A. SurfaceSVPSell9,787$87.08$852,251.96View SEC Filing  
7/5/2016Bryan C. HansonEVPSell15,272$87.11$1,330,343.92View SEC Filing  
6/3/2016Richard KuntzVPSell49,905$82.60$4,122,153.00View SEC Filing  
4/1/2016Richard KuntzVPSell4,000$75.22$300,880.00View SEC Filing  
3/18/2016Shirley A JacksonDirectorSell1,238$75.60$93,592.80View SEC Filing  
3/17/2016Omar IshrakCEOSell23,799$76.15$1,812,293.85View SEC Filing  
3/4/2016Bryan C HansonEVPSell5,000$75.00$375,000.00View SEC Filing  
2/5/2016Bryan C. HansonEVPSell5,000$76.14$380,700.00View SEC Filing  
1/8/2016Bryan C HansonEVPSell5,000$75.00$375,000.00View SEC Filing  
12/4/2015Richard KuntzVPSell13,715$78.06$1,070,592.90View SEC Filing  
9/15/2015Omar IshrakCEOSell20,000$69.43$1,388,600.00View SEC Filing  
7/14/2015Carol A SurfaceSVPSell13,722$75.83$1,040,539.26View SEC Filing  
4/6/2015Richard KuntzVPSell31,768$77.39$2,458,525.52View SEC Filing  
3/25/2015Gary Lee EllisCFOSell43,183$77.81$3,360,069.23View SEC Filing  
3/13/2015Omar IshrakCEOSell20,000$76.24$1,524,800.00View SEC Filing  
2/19/2015Christopher J OconnellEVPSell50,361$78.22$3,939,237.42View SEC Filing  
12/19/2014Richard KuntzVPSell12,855$74.54$958,211.70View SEC Filing  
12/2/2014Shirley A JacksonDirectorSell1,102$74.43$82,021.86View SEC Filing  
11/28/2014Christopher J OconnellEVPSell42,921$73.95$3,174,007.95View SEC Filing  
10/6/2014Christopher J OconnellEVPSell15,388$64.98$999,912.24View SEC Filing  
8/26/2014Christopher J OconnellEVPSell28,000$63.57$1,779,960.00View SEC Filing  
8/26/2014Shirley A JacksonDirectorSell2,769$63.66$176,274.54View SEC Filing  
4/17/2014Catherine SzymanVPSell29,420$58.79$1,729,601.80View SEC Filing  
4/9/2014Richard KuntzVPSell2,512$60.98$153,181.76View SEC Filing  
4/1/2014Gary Lee EllisCFOSell4,246$61.48$261,044.08View SEC Filing  
3/28/2014Christopher OconnellEVPSell1,982$60.39$119,692.98View SEC Filing  
3/20/2014Catherine SzymanVPSell14,979$59.57$892,299.03View SEC Filing  
3/14/2014Omar IshrakCEOSell10,000$59.12$591,200.00View SEC Filing  
3/10/2014Neil AyotteVPSell1,845$59.64$110,035.80View SEC Filing  
12/4/2013Neil AyotteVPSell1,729$57.14$98,795.06View SEC Filing  
9/13/2013Omar IshrakCEOSell10,000$53.58$535,800.00View SEC Filing  
8/26/2013Catherine SzymanVPSell56,998$52.60$2,998,094.80View SEC Filing  
8/22/2013H James DallasVPSell32,332$53.19$1,719,739.08View SEC Filing  
8/21/2013H James DallasVPSell36,256$52.82$1,915,041.92View SEC Filing  
8/21/2013Shirley JacksonDirectorSell8,033$52.84$424,463.72View SEC Filing  
7/11/2013Christopher J OconnellEVPSell30,429$52.92$1,610,302.68View SEC Filing  
7/11/2013Gary Lee EllisCFOSell32,602$53.62$1,748,119.24View SEC Filing  
7/11/2013H James DallasVPSell69,889$53.72$3,754,437.08View SEC Filing  
7/1/2013H James DallasVPSell20,579$52.10$1,072,165.90View SEC Filing  
6/26/2013D Cameron FindlayVPSell75,042$52.20$3,917,192.40View SEC Filing  
6/19/2013H James DallasVPSell94,117$52.74$4,963,730.58View SEC Filing  
5/22/2013Richard H AndersonDirectorBuy4,800$52.32$251,136.00View SEC Filing  
5/10/2013Jack W SchulerDirectorSell34,230$48.24$1,651,255.20View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Medtronic PLC (NYSE:MDT)
Latest Headlines for Medtronic PLC (NYSE:MDT)
DateHeadline logoMedtronic PLC (MDT) Stock Rating Reaffirmed by Royal Bank Of Canada - August 21 at 10:12 AM logoMedtronic (MDT) Q1 Earnings: Stock Likely to Beat Again? - Nasdaq - August 19 at 12:15 AM logoWhat Investors Can Expect from Medtronic’s Fiscal 1Q18 Results - August 19 at 12:15 AM logoMedtronic (MDT) Q1 Earnings: Stock Likely to Beat Again? - August 19 at 12:15 AM logoWill Medtronic Maintain Its Revenue Growth Momentum in Fiscal 1Q18? - August 19 at 12:15 AM logoWill Medtronic Meet Analysts’ Earnings Estimates in Fiscal 1Q18? - August 19 at 12:15 AM logo3 Healthcare Stocks I'll Hold Forever - August 19 at 12:15 AM logoShould You Sell Medtronic (MDT) Before Earnings? - Nasdaq - August 18 at 6:39 AM logoMedtronic EVP & CFO Karen L. Parkhill to Speak at Intellisight 2017 Conference - August 18 at 6:38 AM logoShould You Sell Medtronic (MDT) Before Earnings? - August 17 at 2:27 AM logo3 Dividend Healthcare Stocks - August 16 at 8:28 AM logoMedtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2018 - August 16 at 6:04 AM logoExpect more CEOs to speak out on vital issues, risking the wrath of the Trump, says former Medtronic CEO - August 15 at 9:27 AM logoMedtronic PLC (NYSE:MDT) Set to Announce Quarterly Earnings on Tuesday - August 15 at 2:16 AM logoMedtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology - August 15 at 1:23 AM logoComparing Medtronic PLC (NYSE:MDT) and Integer Holdings (ITGR) - August 10 at 8:22 PM logoHead-To-Head Review: Integer Holdings (ITGR) & Medtronic PLC (MDT) - August 10 at 9:52 AM logoSee what the IHS Markit Score report has to say about Medtronic PLC. - August 10 at 5:01 AM logoMedtronic PLC (NYSE:MDT) Given Consensus Rating of "Hold" by Brokerages - August 8 at 6:44 PM logoMedtronic PLC (NYSE:MDT) Expected to Announce Earnings of $1.08 Per Share - August 8 at 10:28 AM logoInteger Holdings (ITGR) & Medtronic PLC (NYSE:MDT) Critical Review - August 6 at 12:34 AM logoMedtronic PLC (NYSE:MDT) Cut to Sell at BidaskClub - August 5 at 1:38 PM logoLeerink Swann Weighs in on Medtronic PLC's Q1 2018 Earnings (MDT) - August 4 at 3:48 PM logoTop Analyst Reports for Chevron, Wells Fargo & Medtronic - August 4 at 1:33 AM logoLeerink Swann Weighs in on Medtronic PLC's Q2 2018 Earnings (NYSE:MDT) - August 3 at 2:44 PM logoMedtronic PLC (MDT) versus Integer Holdings (ITGR) Head-To-Head Contrast - August 3 at 8:08 AM logoMedtronic's Avalus valve OK'd in U.S. and Europe - August 3 at 4:49 AM logoFIRE AND ICE Trial Analysis Shows Medtronic Cryoballoon Reduces Healthcare System Costs and Utilization - August 3 at 4:49 AM logoMedtronic Plc – Value Analysis (NYSE:MDT) : August 1, 2017 - August 2 at 5:08 AM logoMedtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with ... - GlobeNewswire (press release) - August 1 at 1:07 AM logoMedtronic's CoreValve Evolut Pro CE Mark'd, commercial launch commences - July 31 at 8:05 PM logoZacks Investment Research Lowers Medtronic PLC (MDT) to Sell - July 31 at 12:44 PM logoCardinal Health completes acquisition of Medtronic's patient recovery business; shares up 1% - July 31 at 12:41 PM logoMedtronic Completes Sale of a Portion of Its Patient Monitoring & Recovery Division to Cardinal Health - GlobeNewswire (press release) - July 30 at 7:04 PM logoMedtronic Completes Sale of a Portion of Its Patient Monitoring & Recovery Division to Cardinal Health - July 30 at 7:04 PM logoFinancial Contrast: Integer Holdings (ITGR) vs. Medtronic PLC (NYSE:MDT) - July 28 at 7:42 AM logo3 Dividend Stocks That Should Pay You the Rest of Your Life - July 26 at 5:52 PM logoOp-Ed: Here's the dilemma for GE's new CEO - July 24 at 2:23 PM logoFinancial Contrast: Medtronic PLC (NYSE:MDT) & Globus Medical (GMED) - July 22 at 8:29 AM logoMedtronic's Diabetes Segment Generating Excitement - Seeking Alpha - July 22 at 6:25 AM logoZacks: Analysts Anticipate Medtronic PLC (NYSE:MDT) Will Post Quarterly Sales of $7.47 Billion - July 21 at 7:58 PM logoThe Best Stock in Minnesota: Medtronic - July 21 at 2:09 AM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Medtronic plc - July 20 at 1:00 AM logoINVESTOR ALERT: Goldberg Law PC Announces an Investigation of Medtronic plc - July 20 at 1:00 AM logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Medtronic plc Investors - July 20 at 12:59 AM logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Medtronic plc and Advises Investors with Losses to Contact the Firm - July 20 at 12:59 AM logoQ2 2019 EPS Estimates for Medtronic PLC Reduced by William Blair (MDT) - July 19 at 3:10 PM logoHead to Head Comparison: Globus Medical (GMED) and Medtronic PLC (MDT) - July 19 at 12:24 PM logo$1.08 Earnings Per Share Expected for Medtronic PLC (MDT) This Quarter - July 19 at 12:21 PM logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medtronic plc - MDT - PR Newswire (press release) - July 19 at 4:20 AM



Medtronic PLC (MDT) Chart for Monday, August, 21, 2017

This page was last updated on 8/21/2017 by Staff